PRIMA‐1 and APR‐246 have been shown to possess tumor-suppressive features on cells from diverse origins that express mutant p53, for example, sarcomas, mammary carcinomas, fibrosarcomas, small cell lung cancer, oesophageal adenocarcinoma and breast cancer [691, 697–699]. Here, TP53 is linked to neoplasm.